Peptide stacks for women over 50: what the science supports

What did @magdasantiago1 actually say?

The creator walked through a multi-peptide regimen she takes daily, including oral BPC-157/TB-500, injectable semorelin, a GLP-1 compound she calls "Tri-pepotite," GHK-Cu injections, and a new combo pill she calls the "Thrill Pill" containing PT-141, oxytocin, and tadalafil. She credited BPC-157/TB-500 with healing a muscle strain in about seven days and reducing knee pain from arthritis. She described semorelin as preserving muscle mass when used alongside a GLP-1, and GHK-Cu as an "anti-aging" peptide that "robs your body from the inside out" and stimulates collagen. She also mentioned the combo pill as something that helps libido in menopausal women and supports erections in men. Throughout, she mentioned everything is sourced through a telehealth company and a 503B pharmacy, and noted she essentially gets her peptides free through a referral-style program.

Does the science back this up?

Some of it does, partially. But the evidence quality varies enormously across this stack, and a few claims are ahead of what the data actually supports.

BPC-157 has shown genuinely interesting results in animal models for tendon, muscle, and joint repair. A 2018 review by Chang et al. in Current Pharmaceutical Design summarized preclinical data showing accelerated healing of soft tissue injuries. The problem: almost all of that data is in rodents. There are no completed randomized controlled trials in humans as of 2024. Attributing a seven-day muscle strain recovery specifically to BPC-157 in oral capsule form is a stretch, since oral bioavailability of peptides is a real barrier and the human evidence simply isn't there yet.

GHK-Cu has a more robust topical evidence base. A 2015 review by Pickart and Margolina in Cosmetics documented its role in stimulating collagen synthesis and wound healing. Injectable use for systemic anti-aging is less studied and the "robs your body from the inside out" framing is marketing language, not a clinical description.

Semorelin is an FDA-approved GHRH analog, so it has a legitimate regulatory history, though its current use here is off-label. GLP-1 receptor agonists do have some emerging data on inflammation and joint pain, though the primary indication is metabolic. PT-141 (bremelanotide) is actually FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, so that mention has real clinical backing. Tadalafil is also FDA-approved for erectile dysfunction. Oxytocin in oral or sublingual form has poor bioavailability and limited controlled evidence for the uses described.

What did they get wrong (or right)?

Credit where it's due: pointing people toward a telehealth doctor and a 503B-licensed compounding pharmacy is genuinely more responsible than buying peptides from a research chemical site. That matters.

But several things are overstated or just wrong. First, attributing a specific healing timeline to BPC-157 in oral form ignores that we do not have human clinical trial data confirming this effect, and oral peptide absorption is notoriously unreliable. Claiming it "literally" fixed a strain in seven days is anecdote, not evidence.

Second, describing GHK-Cu as something that "robs your body from the inside out" is not a clinical claim, it's a sales pitch. It raises a flag because she later mentions she profits from peptide referrals, which is a conflict of interest she discloses casually but doesn't frame as one.

Third, the "Thrill Pill" combo of PT-141, oxytocin, and tadalafil is a compounded product mixing an FDA-approved drug (tadalafil) with a peptide with limited oral bioavailability (oxytocin) and another FDA-approved drug (PT-141 as Vyleesi). Compounded combinations are not FDA-approved and should not be treated as equivalent to approved medications. Recommending this for men and women without medical consultation context is a problem.

Finally, the referral program she describes, where she gets her medications free by signing people up, is a financial incentive that colors every recommendation she makes in this video.

What should you actually know?

If you're considering any of these compounds, a few things are worth knowing before you order anything.

• BPC-157 and TB-500 are not FDA-approved for any human indication. All human-relevant data is either preclinical or anecdotal. Using them is off-label at best, experimental at worst.
• Semorelin does have an FDA history as a diagnostic agent and has been used off-label in adults, but that off-label use should be supervised by a prescribing physician who has reviewed your labs.
• GLP-1 receptor agonists are powerful metabolic drugs with real side effect profiles. The claim that a GLP-1 helps with hot flashes and joint pain has some early supportive data but is not an established indication.
• PT-141 (bremelanotide) is FDA-approved only for premenopausal women with acquired hypoactive sexual desire disorder, not as a general libido booster for postmenopausal women or men.
• A 503B outsourcing facility is not the same as a retail compounding pharmacy, and neither produces FDA-approved drugs. Pharma-grade sourcing reduces contamination risk but does not validate the clinical claims being made about the compounds.